- Latest week
- 25 Sep 2026
- Weekly close
- 67,400.00 ARS
- Fair value
- 43,839.45 ARS
Seven-day news read · 23–29 September 2026
Recent company news is balanced
Stored company coverage from the last seven days has not established a clear directional balance.
Company-specific coverage
The news behind the seven-day read
Newest first. The seven-day balance describes these headlines; the weighted score uses a longer 30-day evidence window.
- Business Wire · Main companyAstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
- Zacks · Main companyIs AstraZeneca's Oncology Portfolio Positioned for Continued Growth?
- finance.yahoo.com · Provider-linked mentionPerioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
- MT Newswires · Main companyAstraZeneca Gets US FDA Priority Review for Investigative Bladder Cancer Therapy
- Insider Monkey · Main companyAstraZeneca (AZN): Can Precision Medicine Offset a Narrower Breast Cancer Market?
- seekingalpha.com · Main companyAstraZeneca granted EU label expansion for COPD therapy, Trixeo in asthma
- Zacks · Main companyAstraZeneca's Trixeo Secures Approval for Asthma in the EU
Keep the two readings separate
Recent news shows what changed; the score shows the wider tone
A simple description of company headlines published during 23–29 September 2026.
A 30-day reading that gives more weight to newer, directly relevant coverage.